Blueprint Medicines Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Blueprint Medicines (BPMC) Misses Q2 EPS by 14c
July 30, 2020 7:48 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.28), $0.14 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.94 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More